Novo Nordisk has asked the FDA to add semaglutide to a list that would effectively block manufacturing of copycat versions of ...
Novo Nordisk has nominated semaglutide for inclusion in the FDA’s Demonstrable Difficulties for Compounding list, which ...
Novo Nordisk wants the Food and Drug Administration (FDA) to prevent compounding pharmacies from manufacturing their own ...
Novo Nordisk’s aim with this nomination is to ensure that patients receive only FDA-approved, safe, and effective ...
The agency posted documents this week that the drugmaker had requested the drug be placed on the FDA's "Demonstrable ...
The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 ...